Senses

ReNeuron Provides Business Update and Results Notification

Retrieved on: 
Wednesday, May 8, 2019
Blindness, Vision, Channelopathies, RTT, Retinitis pigmentosa, Senses, Perception, Retinitis, Retina

LONDON, May 8, 2019 /PRNewswire/ --ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, announced a year-end business update ahead of its preliminary results for the year ended March 31, 2019, which will be announced on Thursday, July 11, 2019.

Key Points: 
  • LONDON, May 8, 2019 /PRNewswire/ --ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, announced a year-end business update ahead of its preliminary results for the year ended March 31, 2019, which will be announced on Thursday, July 11, 2019.
  • ReNeuron has made significant progress advancing the clinical development of the Company's human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).
  • ReNeuron will announce its preliminary results for the year ended March 31, 2019 on Thursday, July 11, 2019.
  • This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto.

Global Intraocular Lens Market - Growth, Trends, and Forecast (2019 - 2024) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 8, 2019
Manufacturing, Other Manufacturing, Senses, Perception, Vision, Light, Eye, Ophthalmology, Corrective lenses, Lenses, Intraocular lens, Cataract, Cataract surgery

The "Intraocular Lens Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intraocular Lens Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global intraocular lens was valued USD 3,825.6 in 2018 and is expected to witness a CAGR of 4.89% over the period, 2018-2024 (henceforth, the forecast period).
  • The key factors propelling the intraocular lens market are increasing ophthalmic issues, growing cases of cataract in the diabetic population, and rising adoption of advanced premium IOLs.
  • Thus, increasing costs of IOLs and poor reimbursement coverage are expected to hamper the market growth, over the forecast period.

Kaia Health's App-Based Back Pain Treatment Outperforms Standard Physiotherapy in Clinical Trial

Retrieved on: 
Tuesday, May 7, 2019
Perception, Pain, Human back, Senses, Medicine, Nociception, Acute pain, Back pain, Low back pain

"As a company, we want to support the improvement of the current standard of care for people living with back pain," said Konstantin Mehl, Founder and CEO, Kaia Health.

Key Points: 
  • "As a company, we want to support the improvement of the current standard of care for people living with back pain," said Konstantin Mehl, Founder and CEO, Kaia Health.
  • Both the control and Kaia app treatment groups experienced significant pain reduction over the course of 12 weeks.
  • The decrease suggests Kaia may be an effective treatment for low back pain over a 3-month timeframe.
  • App-based multidisciplinary back pain treatment versus combined physiotherapy plus online education: A randomized controlled trial.

Post-Operative Pain - Pipeline Review, H1 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 2, 2019
Surgery, Health, Pharmaceutical, Perception, Nociception, Senses, Pipeline, Drug pipeline, Pain

The "Post-Operative Pain - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Post-Operative Pain - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.
  • The Post-Operative Pain (Central Nervous System) pipeline guide also reviews key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

SightGlass Vision Presents Clinical Trial Data From Novel Lenses to Control Nearsightedness at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on: 
Thursday, May 2, 2019
Perception, Senses, Light, Optometry, Ophthalmology, Vision, Visual acuity, Near-sightedness, Corrective lens, Contrast, Lens, Visual system

Lenses were designed to modulate contrast in the periphery of the visual field at three different levels.

Key Points: 
  • Lenses were designed to modulate contrast in the periphery of the visual field at three different levels.
  • The primary outcome variables were distance visual acuity, contrast sensitivity, and subjective responses of acceptability assessed using a questionnaire.
  • SightGlass expects to report initial results from the CYPRESS study in 2020, followed by additional data with longer-term follow up.
  • Headquartered in Palo Alto, CA, SightGlass is developing innovative spectacle lenses to reduce the progression of myopia in children.

Five Young Scientists Win EFIC-Grünenthal Grant 2018

Retrieved on: 
Thursday, May 2, 2019
Perception, Acute pain, European Pain Federation EFIC, Senses, Pain management, Pain

With a total value of 200,000, this biennial grant supports young scientists in their quest to turn creative ideas into research projects that deliver life-changing pain management approaches.

Key Points: 
  • With a total value of 200,000, this biennial grant supports young scientists in their quest to turn creative ideas into research projects that deliver life-changing pain management approaches.
  • This is the challenge that the European Pain Federation EFIC and Grnenthal are seeking to tackle together through the EFIC-Grnenthal Grant (E-G-G).
  • The E-G-G aims to raise awareness about unmet needs in pain management and to support young pain scientists in exploring novel ideas for research projects.
  • The E-G-G helps young scientists who are beginning their careers and gives them an opportunity to explore creative approaches to clinical research with the potential to improve pain therapy."

Five Young Scientists Win EFIC-Grünenthal Grant 2018

Retrieved on: 
Thursday, May 2, 2019
Perception, Acute pain, European Pain Federation EFIC, Senses, Pain management, Pain

With a total value of 200,000, this biennial grant supports young scientists in their quest to turn creative ideas into research projects that deliver life-changing pain management approaches.

Key Points: 
  • With a total value of 200,000, this biennial grant supports young scientists in their quest to turn creative ideas into research projects that deliver life-changing pain management approaches.
  • This is the challenge that the European Pain Federation EFIC and Grnenthal are seeking to tackle together through the EFIC-Grnenthal Grant (E-G-G).
  • The E-G-G aims to raise awareness about unmet needs in pain management and to support young pain scientists in exploring novel ideas for research projects.
  • The E-G-G helps young scientists who are beginning their careers and gives them an opportunity to explore creative approaches to clinical research with the potential to improve pain therapy."

BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting

Retrieved on: 
Thursday, May 2, 2019
Health, Biotechnology, Clinical trials, Optical, Vision, Perception, Senses, Ophthalmology, Optometry, Visual acuity, Visual perception, Doheny Eye Institute, Doheny, Retina

One instance of retinal detachment occurred in a patient who was legally blind prior to treatment.

Key Points: 
  • One instance of retinal detachment occurred in a patient who was legally blind prior to treatment.
  • One instance of a severe ERM required surgical removal, which was successful, and the subject continues to demonstrate improved visual acuity from baseline following OpRegen administration.
  • These observations are being independently evaluated by the Doheny Eye Institute and Doheny Image Reading & Research Lab (DIRRL), Los Angeles, CA.
  • BioTime cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

STAAR Surgical Announces Expanded Recommended Diopter Range for EVO Visian ICL by Refractive Societies in Germany and Japan

Retrieved on: 
Wednesday, May 1, 2019
Surgery, Health, Medical devices, Optical, Optics, Eye surgery, Corrective lenses, Refraction, Refractive surgery, Ophthalmology, Vision, Senses, Perception, ICL, Intraocular lens

Caren Mason, President and CEO of STAAR Surgical, stated, Germany and Japan are two highly-respected countries known for their high regulatory standards, precision and quality.

Key Points: 
  • Caren Mason, President and CEO of STAAR Surgical, stated, Germany and Japan are two highly-respected countries known for their high regulatory standards, precision and quality.
  • We are pleased with the modified KRC recommendations and see ample growth opportunities in the lower diopter segment of refractive vision correction for the EVO Visian ICL, said the EVO Visian ICL Expert Group based in Germany.
  • STAARs lens used in refractive surgery is called an Implantable Collamer Lens or ICL, which includes the EVO Visian ICL product line.
  • The Visian ICL with CentraFLOW, now known as EVO Visian ICL, is not yet approved for sale in the United States.

Alcon to Showcase New Clinical Data, Innovative Technology at American Society of Cataract and Refractive Surgery 2019 Annual Meeting

Retrieved on: 
Wednesday, May 1, 2019
Surgery, Health, Biotechnology, Medical devices, Optical, Medicine, Medical specialties, Eye surgery, Senses, Eye, Ophthalmology, Vision, Cataract surgery, Lenses, ASCRS, Cataract, Refractive surgery

Alcon, the global leader in eye care dedicated to helping people see brilliantly, will feature new clinical data along with innovative product designs and technology for the Cataract Refractive Suite during the American Society of Cataract and Refractive Surgery (ASCRS) 2019 annual meeting, taking place May 3-7 in San Diego, CA.

Key Points: 
  • Alcon, the global leader in eye care dedicated to helping people see brilliantly, will feature new clinical data along with innovative product designs and technology for the Cataract Refractive Suite during the American Society of Cataract and Refractive Surgery (ASCRS) 2019 annual meeting, taking place May 3-7 in San Diego, CA.
  • In an effort to improve safety, consistency and control during cataract surgery, Alcon will launch the ACTIVE SENTRY Handpiece and INTREPID Hybrid Tip.
  • Alcon will feature two technologies that aim to improve surgeon visualization during cataract surgery.
  • Paper Presentation: Use of a Refractive Analysis Database for Intraocular Lens Power Optimization in Cataract Surgery, Presented by Dr. Robert J. Cionni et al.